Filing Flows › Comparisons › TXG vs QTRX
10x Genomics vs Quanterix: TXG and QTRX compared
10x Genomics is the larger company: $151M of revenue in its latest quarter (Q3 2026) against $35.0M for Quanterix (Q3 2026). 10x Genomics is growing faster (+1% against -13% a year earlier). 10x Genomics is more profitable, with an operating margin of -10.7% against -64.3%.
Where the money goes: TXG and QTRX
10x Genomics (TXG) · Q3 2026
10x Genomics, Q3 2026: revenue $151M (+1% year over year), operating margin -10.7%, net loss $19.4M, operating cash flow $15.8M. The chart follows the revenue to costs, profit and cash.
Quanterix (QTRX) · Q3 2026
Quanterix, Q3 2026: revenue $35.0M (-13% year over year), operating margin -64.3%, net loss $21.6M, operating cash flow −$16.2M. The chart follows the revenue to costs, profit and cash.
| 10x Genomics (TXG) | Quanterix (QTRX) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $151M | $35.0M |
| Revenue growth, Y/Y | +1% | -13% |
| Operating margin | -10.7% | -64.3% |
| Net earnings | −$19.4M | −$21.6M |
| Net margin | -12.9% | -61.7% |
| Operating cash flow | $15.8M | −$16.2M |
| Free cash flow | $14.9M | — |
| Market value | — | $147M |
| Analysts’ mean target | — | $3.17 |
Where the revenue comes from
10x Genomics
- Consumables: $134M (89%)
- Services: $9.0M (6%)
- Instruments: $6.9M (5%)
Quanterix
- Product revenue: $25.1M (72%)
- Service and other revenue: $9.4M (27%)
- Collaboration and license revenue: $422K (1%)
Questions
Which is bigger, 10x Genomics or Quanterix?
10x Genomics is the larger company: $151M of revenue in its latest quarter (Q3 2026) against $35.0M for Quanterix (Q3 2026).
Is 10x Genomics or Quanterix growing faster?
10x Genomics is growing faster (+1% against -13% a year earlier).
Which is more profitable, 10x Genomics or Quanterix?
10x Genomics is more profitable, with an operating margin of -10.7% against -64.3%.
More: 10x Genomics earnings · how 10x Genomics makes money · Quanterix earnings · how Quanterix makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 6, 2026; 10-Q filed Nov 9, 2026). Fiscal quarters can end on different dates. Not investment advice.